Brazil’s 90‑Business‑Day ANVISA Clock: How to Plan First‑in‑Human Activation Without Bottlenecks

Brazil has moved from “unpredictable timelines” to a more clock-driven model for key clinical trial petitions. According to the U.S. NIH ClinRegs Brazil overview, Law No. 14.874 requires ANVISA’s analysis of primary petitions for clinical trials (including Clinical Drug Development Dossiers, DDCMs) to be completed within 90 business days. This is a meaningful planning advantage for MedTech and Biopharma teams designing first‑in‑human (FIH) or other early-stage studies in Latin America.

But a defined regulator timeline does not automatically translate into a fast first-patient-in. Activation can still stall due to ethics sequencing, site contracts, import permits, labeling, budgeting, and operational readiness. The sponsors who benefit most are the ones who orchestrate the entire activation system around the review clock—not just the regulatory submission.

This article provides a practical playbook for using Brazil’s defined review window to reduce uncertainty without compromising compliance. It is written for MedTech founders, clinical operations leaders, and regulatory directors planning early clinical evidence generation in Latin America.

1) What the “90‑business‑day clock” means (and what it doesn’t)

In many countries, the biggest activation challenge is not the technical content of the dossier—it is uncertainty. When timelines drift, every downstream dependency becomes harder: site selection, device logistics, vendor contracting, and financing.

Brazil’s framework has introduced a clearer expectation. ClinRegs summarizes that ANVISA’s analysis of primary petitions for clinical trials with human beings “must be completed within 90 business days” under Law No. 14.874, with related implementing details in Resolução RDC No. 945 (including how the 90 business days are counted for DDCM/DEEC petitions).

Important nuance: a regulator timeline is one piece of a multi-track activation pathway. If the sponsor treats the ANVISA clock as the entire schedule, they can still lose weeks or months elsewhere.

2) Build an activation timeline like a network, not a checklist

Fast activation is usually the result of parallelization, not heroics. A useful way to plan is to treat each workstream as a node in a network:

• Regulatory dossier readiness (DDCM/DEEC content, translations, country-specific annexes)
• Ethics committee readiness (Brazil CEP/CONEP strategy, submissions, anticipated questions)
• Site readiness (feasibility, equipment, training, contracts, budgets)
• Import and logistics readiness (customs broker, labeling, packaging, temperature control, returns)
• Data and safety operations (eCRF build, SAE workflows, vendor setup, monitoring plan)

In early-stage MedTech programs, the “critical path” often shifts midstream. For example, the device may be available, but site contract negotiation drags. Or the site is ready, but import documentation is incomplete. A network view helps you see what must be done in parallel so that the 90-day review window is not wasted.

3) A practical pre-submission readiness package (what to have done before day 0)

To benefit from predictable review windows, sponsors should aim to begin ANVISA review with minimal “churn” during the clock. In practice, this means building a readiness package before the submission date. Common elements include:

• Protocol that is operationally executable: endpoints, visit schedule, and device handling that local sites can implement.
• Risk-driven monitoring and safety plan: proportional to first-in-human risk, with clearly defined escalation pathways.
• Brazil-ready informed consent: culturally appropriate language; processes for re-consent if amendments occur.
• Import map: who will act as importer-of-record, how devices will be labeled, and the evidence trail for traceability.
• Site contracts and budgets in draft form: so legal review does not become the gating item after regulatory clearance.

Internal experience across Latin America shows that when sponsors plan only the submission, they often discover the “real bottleneck” later. Conversely, when they package readiness early, they can compress time-to-site-initiation after regulatory clearance.

4) Common activation bottlenecks in Brazil (and how to design around them)

Even with a defined regulator timeline, teams can lose time in avoidable areas. Here are recurring bottlenecks and practical ways to design around them:

• Ethics sequencing misunderstandings: plan early for CEP/CONEP pathways and expected document sets; align translations and investigator documents up front.
• Device logistics not protocolized: define receipt, storage, accountability, and disposal processes inside the protocol and site manuals.
• Training delays: schedule investigator meetings and device training as soon as sites are selected; do not wait for final approvals to build training assets.
• Budget misalignment: ensure site budgets reflect local realities (procedures, imaging, follow-up) to reduce renegotiation cycles.

Operationally, the fastest programs are those where regulatory and operations leaders co-own the activation timeline, instead of treating it as a handoff from “regulatory” to “clinops.”

5) How to use Brazil’s timeline advantage in a multi-country Latin America strategy

Brazil’s defined review window can be especially valuable when used as one “anchor country” in a broader Latin America evidence strategy. Sponsors often seek to generate credible early data quickly, then expand into additional markets.

To do this effectively:

1. Design the protocol for exportability: align endpoints and data standards with future regulatory and reimbursement conversations.
2. Standardize your core dossier: build a master package that can be adapted for different authorities without reinventing content.
3. Plan the expansion pathway early: identify which countries can open in parallel (based on timelines, import complexity, and site readiness).

For example, NIH ClinRegs indicates Peru’s INS must complete review and approval of a clinical trial application within a maximum of 30 working days, which may influence sequencing decisions depending on site availability and import readiness. The right path depends on the sponsor’s risk tolerance, funding timeline, and clinical endpoints.

FAQ: Brazil’s ANVISA clock and first‑in‑human planning

How long does ANVISA have to review key clinical trial petitions in Brazil?

NIH ClinRegs summarizes that, under Law No. 14.874, ANVISA’s analysis of primary petitions for clinical trials (including DDCMs) must be completed within 90 business days.

Does a 90-business-day regulator timeline guarantee fast first-patient-in?

No. Activation speed depends on the entire system: ethics reviews, site contracts, import logistics, training, and operational readiness. A defined review window reduces uncertainty, but sponsors still need parallel planning.

What is the biggest mistake sponsors make when planning first‑in‑human studies in Brazil?

Treating regulatory submission as the whole project. The most common failure mode is not “regulatory delay”—it is downstream operational bottlenecks that were not designed into the timeline.

Bottom line: Brazil’s defined review timeline can be a real advantage for early-stage programs, but only if sponsors plan activation as a coordinated set of parallel workstreams. If you treat the 90-day clock as a project management tool—not just a legal detail—you can reduce uncertainty and protect your first-patient-in date.